Results 21 to 30 of about 7,956,506 (236)

Diagnosis and classification of optic neuritis [PDF]

open access: yes, 2022
There is no consensus regarding the classification of optic neuritis, and precise diagnostic criteria are not available. This reality means that the diagnosis of disorders that have optic neuritis as the first manifestation can be challenging.
Diem, Ricarda,   +228 more
core   +2 more sources

The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments. [PDF]

open access: yes, 2011
BACKGROUND: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a
Kolappan, Madhan   +73 more
core   +4 more sources

Clinical profile and short-term outcomes of optic neuritis patients in India

open access: yesIndian Journal of Ophthalmology, 2014
Purpose: To evaluate the clinical profile and short-term visual outcome of optic neuritis (ON) patients in India. Materials and Methods: In this prospective study carried out over a period of 3 years, 99 eyes of 83 ON patients were examined and followed ...
Rohit Saxena   +5 more
doaj   +1 more source

Oral lipoic acid as a treatment for acute optic neuritis: a blinded, placebo controlled randomized trial

open access: yesMultiple Sclerosis Journal - Experimental, Translational and Clinical, 2019
Background Lipoic acid, an antioxidant, has beneficial effects in experimental acute optic neuritis and autoimmune encephalomyelitis. Optical coherence tomography can detect retinal nerve fiber layer thinning, representing axonal degeneration ...
Julie Falardeau   +9 more
doaj   +1 more source

Efficacy of vision restoration therapy after optic neuritis (VISION study): study protocol for a randomized controlled trial

open access: yesTrials, 2012
Background Optic neuritis is a frequent manifestation of multiple sclerosis. Visual deficits range from a minor impairment of visual functions through to complete loss of vision.
Schinzel Johann   +7 more
doaj   +1 more source

The Optic Neuritis Treatment Trial [PDF]

open access: yesArchives of Ophthalmology, 2008
T HE OPTIC NEURITIS TREATMENT TRIAL (ONTT)hashadahighly significant impact on thepracticesofophthalmologyandneurology. The impact can be attributed to its systematic collection and analysis of enormousamountsofdata,adherencetosoundclinicaltrialmethodology, as well as important unanticipated findings.
openaire   +2 more sources

Patients' knowledge and perception on optic neuritis management before and after an information session

open access: yesBMC Ophthalmology, 2010
Background Patients' understanding of their condition affect the choice of treatment. The aim of this study is to evaluate patients' understanding and treatment preferences before and after an information session on the treatment of acute optic neuritis.
Klaer Pamela   +4 more
doaj   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec   +6 more
wiley   +1 more source

The contribution of brain reorganisation to recovery in patients with optic neuritis [PDF]

open access: yes, 2010
In this thesis, the mechanisms of damage and repair in clinically isolated optic neuritis (ON) were investigated in vivo, by combining magnetic resonance imaging (MRI), electrophysiology and optical coherence tomography (OCT).
Jenkins, T.M.
core  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy